In the early years of the smartphone revolution, the tech industry coined a mantra that would eventually bleed into the world of medicine: “There’s an app for that.” As the Apple App Store and Android Market democratized software access, visionaries like cardiologist Eric Topol and physician-innovator Daniel Kraft predicted a seismic shift. They envisioned a future where smartphones and sensors would become as fundamental to clinical practice as the stethoscope, with digital tools prescribed as routinely as life-saving medications.
For years, that vision remained largely aspirational, relegated to the sidelines of traditional medicine. However, a startup named Remepy is now poised to transform that idealism into a tangible, regulatory-cleared reality. By pioneering the concept of “hybrid drugs”—a synthesis of conventional pharmaceuticals and AI-driven, app-delivered treatment protocols—Remepy is bridging the gap between molecular medicine and digital intervention.
The Core Concept: Redefining Multidisciplinary Care
At the helm of this innovation is Dr. Michal Tsur, co-founder and co-CEO of Remepy. Her mission is rooted in a critical observation: modern healthcare is often fragmented. While medical consensus emphasizes that complex, chronic conditions are best managed through multidisciplinary, integrative approaches, the delivery system remains siloed. A patient might receive a prescription for a pill from a neurologist, a separate referral for physical therapy, a recommendation for mental health support, and a list of exercises for speech or motor function.
“Everything we do is built on the understanding that most medical conditions are better treated with a multidisciplinary, integrative approach,” Dr. Tsur explains. “As technology evolves and devices become more powerful, you can deliver, measure, and personalize many types of high-quality intervention through a mobile device.”
Remepy’s “hybrid drug” model effectively collapses these silos. By combining a standard pharmaceutical with a structured, app-based behavioral and physiological protocol, the company aims to offer a single, cohesive, and prescribable product. This approach is not merely about convenience; it is about maximizing therapeutic efficacy in diseases where non-pharmaceutical interventions have proven clinical value but suffer from poor patient adherence.
Learning from the Digital Therapeutics “Winter”
The journey to this point has been informed by the painful lessons of the first wave of digital therapeutics (DTx). The industry witnessed a high-profile cautionary tale in 2023 when Pear Therapeutics—the pioneer that secured the first FDA-cleared prescription digital therapeutic—filed for Chapter 11 bankruptcy. Despite proving that doctors would prescribe the software and that patients would use it, the company failed to bridge the gap toward sustainable, long-term commercial reimbursement.
Remepy has meticulously designed its business model to avoid this pitfall. By integrating software directly with a pharmaceutical product, they are aligning themselves with established pharma economics and regulatory pathways.
“Everything is mechanistically and scientifically proven, and we take it through rigorous clinical trials,” says Tsur. “In the end, it’s a drug and an app.”
By leveraging the FDA’s Prescription Drug Use-Related Software (PDURS) pathway and combination-product regulations, Remepy is positioning its hybrid products to potentially support expanded drug labels. This is a crucial strategic move: it shifts the software from a "standalone" product that struggles for insurance coverage to an integral component of a drug regimen, which has a well-trodden path to reimbursement.
A Breakthrough in Parkinson’s: The Hybridopa Study
The company’s most significant validation to date arrived in May 2026, when they reported robust Phase IIa clinical trial results for "Hybridopa," their lead investigational product for Parkinson’s disease.
The Problem: The Levodopa Ceiling
For decades, carbidopa-levodopa has remained the gold standard for Parkinson’s therapy. However, its effectiveness is not limitless. As the disease progresses, the drug’s benefits often diminish, and motor fluctuations—such as the dreaded “off” periods—become increasingly prevalent. Studies have shown that within five to ten years of treatment, nearly every patient encounters these motor fluctuations.
“For many drugs, there’s a ceiling effect you cannot go beyond without attaching these interventions,” Dr. Tsur notes. Remepy’s hypothesis was simple: Levodopa can do more if it is coupled with a daily, AI-optimized protocol that addresses movement, speech, mood, and cognition—the very areas where the pill alone hits a wall.
The Trial Data
The Phase IIa study, published in Brain Communications, was a three-week, double-blind trial involving 41 participants. All patients continued their existing levodopa doses, but were randomized to use either "DopApp"—the digital component of the Hybridopa system—or a placebo app.
The results were striking:
- Primary Endpoint: The protocol group improved by a mean of 9.7 points on the MDS-UPDRS (Movement Disorder Society’s revision of the Unified Parkinson’s Disease Rating Scale), the global gold standard for assessing Parkinson’s severity.
- Placebo Comparison: The placebo group saw a nominal improvement of only 1.95 points.
- Response Rate: An impressive 90% of patients in the Hybridopa group cleared the five-point response threshold.
To put this in context, traditional carbidopa-levodopa therapy typically reduces the MDS-UPDRS score by eight to ten points on its own. By achieving an additional 9.7-point reduction, the DopApp essentially doubled the clinical effect of the pill.
The Mechanics of the Hybrid Protocol
The DopApp functions as a personalized digital coach. It tracks daily movement against specific goals and prompts the patient to log subjective symptoms like stiffness, tremor, and pain. Using this real-time data, the app’s AI adjusts the daily protocol—which may include specific physiotherapy, occupational exercises, and speech drills—to match the patient’s current functional state.
This solves one of the primary weaknesses of traditional, single-mechanism pharmacology: the "one-size-fits-all" approach.
“Drugs usually have one mechanism,” Dr. Tsur explains. “An app can have many. You overcome individual variation by having a broad set of modalities in diseases with high variation.”
By stacking multiple therapeutic mechanisms (pharmacological + behavioral + cognitive), Remepy can tailor the intervention to the specific phenotype of the patient’s Parkinson’s presentation, which is notoriously heterogeneous.
Implications for the Future of Medicine
The success of Hybridopa signals a potential shift in how chronic diseases are categorized and treated. If the hybrid model continues to prove its worth in Phase III trials, it could fundamentally alter the workflow of neurologists, oncologists, and specialists in women’s health.
Simplifying Clinical Workflow
Currently, a physician must act as a case manager, prescribing a drug and then writing multiple, disjointed referrals for supportive care. By collapsing this into a single, prescribable "hybrid" package, Remepy aims to reduce administrative burden. “We’re making physicians’ lives easier,” Tsur says, “because instead of prescribing a drug and then recommending many other therapies, they just prescribe a hybrid drug.”
Expanding the Therapeutic Window
The implications for patient quality of life are profound. If a digital intervention can reliably extend the efficacy of existing, well-understood drugs, patients may be able to delay the need for higher dosages or more invasive surgical interventions, such as deep brain stimulation (DBS).
The Regulatory Tailwind
By leaning into the PDURS pathway, Remepy is testing a new frontier in the FDA’s oversight. If the software is recognized as part of the drug’s labeling, it sets a precedent for how other manufacturers might incorporate digital components into their own portfolios. This is not just a technological advancement; it is a regulatory evolution that acknowledges that in the 21st century, a molecule alone is rarely enough.
Conclusion: A New Era of Integrated Care
As Remepy looks toward future trials and potential commercialization, the broader medical community is watching closely. The failure of early digital therapeutics left a vacuum that is now being filled by a more sophisticated, evidence-based approach.
By grounding its digital tools in the rigorous framework of traditional pharmacology and focusing on indications where non-pharmaceutical intervention is already clinically proven but operationally difficult, Remepy has moved the conversation from "what could be" to "what is." The hybrid drug may well be the bridge that finally allows medicine to deliver on the early promise of the digital age: a more personalized, effective, and cohesive standard of care.
For the millions of patients living with Parkinson’s disease and other complex, chronic conditions, the "app for that" is no longer just a slogan—it is a prescription for a better life.
About the Author
